Shang Hai Zheng Quan Bao·2025-08-19 19:33Core Viewpoint - Rongchang Biopharmaceutical (Yantai) Co., Ltd. has signed a licensing agreement with Santen Pharmaceutical Co., Ltd.'s wholly-owned subsidiary, Santen China, granting exclusive rights for the development, production, and commercialization of the RC28-E injection in several Asian markets, while retaining global rights outside these regions [2][5]. Group 1: Licensing Agreement Details - The agreement allows Santen China to exclusively develop, produce, and commercialize the RC28-E injection in Greater China, South Korea, Thailand, Vietnam, Singapore, the Philippines, Indonesia, and Malaysia [2][5]. - Rongchang Biopharmaceutical will receive an upfront payment of 250 million RMB, along with potential milestone payments totaling up to 520 million RMB for development and regulatory achievements, and up to 525 million RMB for sales milestones [2][6]. - Additionally, the company will earn a tiered sales commission based on product sales in the licensed regions, ranging from high single-digit to double-digit percentages [6]. Group 2: Product Information - The RC28-E injection is a dual-target fusion protein drug developed by Rongchang Biopharmaceutical for treating ocular neovascular diseases [3]. - The drug has shown promising results in a Phase II clinical trial for diabetic macular edema (DME), demonstrating improvements in best-corrected visual acuity and reductions in central retinal thickness [3]. Group 3: Impact on the Company - This transaction is expected to accelerate market access and patient coverage for RC28-E, significantly shortening the commercialization cycle and providing innovative treatment solutions for retinal diseases [7]. - The agreement does not affect the company's operational independence and does not harm the interests of the company or its shareholders [7].